Vanguard Fiduciary Trust
PRLD icon

Vanguard Fiduciary Trust’s Prelude Therapeutics PRLD Stock Holding History

Vanguard Fiduciary Trust’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.52M Buy
284,886
+127,506
+81% +$555K ﹤0.01% 2828
2026
Q1 		$538K Buy
+157,380
New +$413K ﹤0.01% 3188

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Fiduciary Trust's PRLD Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Prelude Therapeutics (PRLD) stake by 81% in Q2 2026, buying an estimated $555K and bringing the position to 284,886 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2828.

Vanguard Fiduciary Trust first reported a position in PRLD in Q1 2026 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Vanguard Fiduciary Trust held 284,886 shares of Prelude Therapeutics worth $1.52M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 127,506 Prelude Therapeutics shares in Q2 2026, an estimated $555K.
  • Prelude Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2828 holding.
  • Vanguard Fiduciary Trust first reported a position in Prelude Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.